YAP1 and cancer: As a consequence, the Hippo pathway is currently considered a therapeutic target in cancer and several clinical trials have been initiated to systematically analyze the effects of YAP/TAZ inhibition on tumor progression ([5, 12], ClinicalTrials.gov Identifier: NCT02347163).